Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

NICE recommends apalutamide, androgen deprivation therapy to treat prostate cancer

The National Institute for Health and Clinical Excellence (NICE) has recommended apalutamide, sold under the brand name Erleada, and androgen deprivation therapy for treating prostate cancer in adults.

The move will make around 8,000 people with hormone-sensitive or hormone-relapsed prostate cancer eligible for treatment with apalutamide.


The recommendation follows an improved discount to the price of apalutamide offered by its manufacturer Janssen Pharmaceuticals, wholly-owned by Johnson & Johnson.

Apalutamide is a kind of drug called an androgen receptor inhibitor which works by blocking the effect of testosterone on prostate cancer cells.

The clinical trial results suggest apalutamide plus androgen deprivation therapy increases longevity of the patient by slowing down the growth of cancer cells.

Meindert Boysen, NICE deputy chief executive and director of the Centre for Health Technology Evaluation, said: “We are very pleased that Janssen has been able to work with us to address the uncertainties in the evidence identified by the committee in the previous draft guidance.

“This means that we are able to produce final draft guidance recommending apalutamide as an effective and valuable additional treatment option for people with these types of prostate cancer.”

The guidance focused on treating adults who no longer respond to hormone therapy and are at high risk of the cancer spreading to other parts of their body.

More For You

Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less
Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less
Scotland's digital patient care record

The amendment ensures that every person who receives health care or a social service in Scotland will have a digital care record

Pic credit: iStock

Scotland's move to create digital patient care record hailed

The Royal Pharmaceutical Society (RPS) in Scotland has welcomed the decision of the Scottish Parliament to create an integrated digital patient care record.

The move came during a debate on the Care Reform (Scotland) Bill on Tuesday (10), when Jackie Baillie tabled an amendment to ensure that every person who receives health care or a social service in Scotland has a digital care record.

Keep ReadingShow less
A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less